Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer

Androgen deprivation therapy (ADT) has long been the only treatment for metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, with the use of docetaxel chemotherapy and the emergence of various novel hormone therapy drugs, such as Abiraterone, Enzalutamide, Apalutamide, Darolutam...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wei-hua Liu, Jia-tao Yao, Shi-jie Ye, Peng-cheng Hu, Xin Fei, Qi Ma, Hai-chao Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MRE Press 2024-06-01
Edice:	Journal of Men's Health
Témata:	metastatic hormone-sensitive prostate cancer novel hormone therapy androgen deprivation therapy triple therapy combination therapy prostate cancer
On-line přístup:	https://oss.jomh.org/files/article/20240628-294/pdf/JOMH2023101801.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!